

# Jun Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/557902/publications.pdf>

Version: 2024-02-01

10  
papers

75  
citations

1937685  
4  
h-index

1474206  
9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

87  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological characteristic of rubella by age group during 12 years after the national introduction of rubella vaccine in Hangzhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	3.3	2
2	Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 157-161.	3.3	10
3	Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 211-216.	3.3	18
4	Primary immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2008â€“2017. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1239-1243.	3.3	2
5	Hepatitis B virus infection seromarkers among college freshmen and their immune responses to different vaccination policies of hepatitis B vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4587-4594.	3.3	2
6	Seroepidemiology of tetanus in Hangzhou from 2009 to 2018. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2670-2676.	3.3	1
7	Seroepidemiology of pertussis in Hangzhou, China, during 2009â€“2017. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2564-2570.	3.3	4
8	Seroepidemiology of varicella in Hangzhou, China in the vaccine era. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2464-2471.	3.3	10
9	Survey of contraindications in children's routine vaccination in Hangzhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1539-1543.	3.3	2
10	Factors associated with pneumococcal vaccination among an urban elderly population in China. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2994-2999.	3.3	24